NASDAQ:QURE uniQure Q3 2026 Earnings Date & Estimates $21.42 +0.15 (+0.68%) As of 09:54 AM Eastern This is a fair market value price provided by Massive. Learn more. uniQure is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026TimeBefore Market OpensConference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from uniQure in Q3 2026uniQure is expected to post earnings of -$0.9217 per share on revenue of $6.21 million. In the same quarter a year earlier uniQure reported -$1.38 per share on revenue of $3.70 million. uniQure last reported on July 29, 2026, posting -$1.22 per share and missing the -$0.8223 consensus estimate. uniQure has beaten the consensus EPS estimate in 6 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.9217Expected Revenue$6.21 millionPrior-Year EPS-$1.38Prior-Year Revenue$3.70 millionExpected Revenue Growth+67.7%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.22 (Missed by -$0.3977)Last Quarter Revenue$5.84 millionEPS Beat Rate6 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report uniQure Q3 2026 Earnings FAQ When does uniQure report Q3 2026 earnings? uniQure (NASDAQ:QURE) is estimated to report Q3 2026 earnings on Monday, November 9, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is uniQure's Q3 2026 earnings call? uniQure's Q3 2026 earnings conference call is scheduled for Monday, November 9, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for uniQure? Analysts expect uniQure to post earnings of -$0.9217 per share for Q3 2026. How much revenue is uniQure expected to report? The consensus revenue estimate for uniQure is $6.21 million for Q3 2026. uniQure Earnings HeadlinesWhy uniQure (QURE) Is Down 5.9% After Fresh Huntington’s Gene Therapy Data Update And What’s NextOctober 7, 2026 | finance.yahoo.comUNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share DropOctober 6, 2026 | businesswire.comAI Microcap Teams With Gentex on Next-Gen Military HelmetsMorgan Stanley projects the humanoid robotics market could reach $5 trillion by 2050, with more than 1 billion robots operating worldwide. But even the most advanced machines still lack one human sense: smell. One microcap is developing an AI-powered sensor, smaller than a deck of cards, now in hands-on integration with Gentex, whose helmet systems serve U.S. forces and more than 20 NATO nations.October 14 at 1:00 AM | Capital Trends (Ad)uniQure (NASDAQ:QURE) Shares Down 5.5% on Analyst DowngradeOctober 6, 2026 | americanbankingnews.comBarclays Downgrades uniQure to Equal Weight From OverweightOctober 5, 2026 | marketscreener.comMBarclays downgrades uniQure NV to equal-weight from overweightOctober 5, 2026 | msn.comSee More uniQure Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email. Email Address About uniQureuniQure (NASDAQ:QURE) is a biotechnology company focused on developing gene therapies intended to treat serious and potentially life-threatening diseases. The company uses adeno-associated virus (AAV) delivery technology to introduce genetic material into patients’ cells, with the goal of addressing the underlying causes of disease through a single administration. uniQure’s lead commercial product, Hemgenix (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B who use factor IX replacement therapy. Hemgenix was developed by uniQure and is commercialized by CSL under a licensing and collaboration agreement. The company’s investigational pipeline has included gene therapies for Huntington’s disease, epilepsy and other severe conditions. Founded in 1998 as Amsterdam Molecular Therapeutics, uniQure is headquartered in Lexington, Massachusetts, and maintains operations in the Netherlands. Its research, clinical development and commercial activities serve patients and healthcare markets in the United States, Europe and other international regions through internal programs and strategic partnerships.View uniQure ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
